The Interactions Between Ciprofloxacin and Parenteral Nutrition Admixtures

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Jan 2

PMID 31892212

Citations 11

Authors

Aleksandra Gostynska

Maciej Stawny

Katarzyna Dettlaff

Anna Jelinska

Affiliations

Soon will be listed here.

Abstract

Background: Co-infusion of parenteral nutrition (PN) and other drugs increases the risk of the interaction between drug and PN admixtures that can cause embolization of small blood vessels, resulting in potentially fatal consequences, including pulmonary embolism, or liver and retina vascular damage. The present study aimed to determine the compatibility between ciprofloxacin (CF) and eighteen compounded PN admixtures in order to assess the possibility of their co-administration via Y-sites.

Methods: CF and PN admixtures were mixed at two volume ratios (1:1 and 2:1) and potential interactions were examined using visual inspection, and measurements of pH, osmolality particle size, and zeta potential. The analyses were conducted immediately after sample preparation and after four hours of storage.

Results: The compatibility tests showed that the addition of the CF to the PN admixtures did not cause any color change or sign of destabilization in the fat emulsion. However, precipitation was observed in formulations containing higher CF concentrations and, in the case of lower CF concentrations, in formulations containing magnesium and calcium ions at a molar ratio of 2:1.

Conclusions: The administration of CF and PN admixtures via the Y-site should be avoided or performed only with PN admixtures for which compatibility has been confirmed and the CF concentration in samples is 1 mg/mL at a molar ratio of magnesium to calcium ions of 1:1.

Citing Articles

Potential Use of Common Administration of Emulsion for Parenteral Nutrition and Vinpocetine: Compatibility Study and Prospect.

Tomczak S, Kaszuba K, Szkudlarek J, Piwowarczyk L, Jelinska A Metabolites. 2024; 14(8).

PMID: 39195535 PMC: 11356329. DOI: 10.3390/metabo14080439.

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition.

de Pourcq J, Riera A, Gras L, Garin N, Busquets M, Cardenete J Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065746 PMC: 11279994. DOI: 10.3390/ph17070896.

Y-Site Compatibility Studies of Parenteral Nutrition and Other Intravenous Medications in Neonatal and Pediatric Patients: A Review of the Literature Evidence.

Gostynska A, Przybylski T, Ogrodowczyk M Pharmaceutics. 2024; 16(2).

PMID: 38399318 PMC: 10892144. DOI: 10.3390/pharmaceutics16020264.

Honokiol-Loaded Nanoemulsion for Glioblastoma Treatment: Statistical Optimization, Physicochemical Characterization, and an In Vitro Toxicity Assay.

Gostynska A, Czerniel J, Kuzminska J, Brzozowski J, Majchrzak-Celinska A, Krajka-Kuzniak V Pharmaceutics. 2023; 15(2).

PMID: 36839769 PMC: 9959519. DOI: 10.3390/pharmaceutics15020448.

Y-Site Compatibility Studies of Ketoprofen with Parenteral Nutrition Admixtures for Central and Peripheral Administration.

Dettlaff K, Gostynska A, Ziolkowska N, Stawny M Pharmaceutics. 2022; 14(12).

PMID: 36559064 PMC: 9781255. DOI: 10.3390/pharmaceutics14122570.

References

Hill S, Heldman L, Goo E, Whippo P, Perkinson J . Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr. 1996; 20(1):81-7. DOI: 10.1177/014860719602000181. View

WATSON D . Piggyback compatibility of antibiotics with pediatric parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1985; 9(2):220-4. DOI: 10.1177/0148607185009002220. View

Stojkovic A, Tajber L, Paluch K, Djuric Z, Parojcic J, Corrigan O . Biopharmaceutical characterisation of ciprofloxacin-metallic ion interactions: comparative study into the effect of aluminium, calcium, zinc and iron on drug solubility and dissolution. Acta Pharm. 2014; 64(1):77-88. DOI: 10.2478/acph-2014-0007. View

Driscoll D, Ling P, Bistrian B . Pathological consequences to reticuloendothelial system organs following infusion of unstable all-in-one mixtures in rats. Clin Nutr. 2006; 25(5):842-50. DOI: 10.1016/j.clnu.2006.02.009. View

Stawny M, Olijarczyk R, Jaroszkiewicz E, Jelinska A . Pharmaceutical point of view on parenteral nutrition. ScientificWorldJournal. 2014; 2013:415310. PMC: 3885274. DOI: 10.1155/2013/415310. View

Breda S, Jimenez-Kairuz A, Manzo R, Olivera M . Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives. Int J Pharm. 2009; 371(1-2):106-13. DOI: 10.1016/j.ijpharm.2008.12.026. View

Kanji S, Lam J, Johanson C, Singh A, Goddard R, Fairbairn J . Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units. Crit Care Med. 2010; 38(9):1890-8. DOI: 10.1097/CCM.0b013e3181e8adcc. View

Newton D . Drug incompatibility chemistry. Am J Health Syst Pharm. 2009; 66(4):348-57. DOI: 10.2146/ajhp080059. View

Stawny M, Gostynska A, Dettlaff K, Jelinska A, Glowka E, Ogrodowczyk M . Effect of Lipid Emulsion on Stability of Ampicillin in Total Parenteral Nutrition. Nutrients. 2019; 11(3). PMC: 6470911. DOI: 10.3390/nu11030559. View

10.

Taxis K, Barber N . Ethnographic study of incidence and severity of intravenous drug errors. BMJ. 2003; 326(7391):684. PMC: 152365. DOI: 10.1136/bmj.326.7391.684. View

11.

Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J . Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab. 2018; 73(3):227-233. DOI: 10.1159/000492940. View

12.

Driscoll D, Ling P, Silvestri A, Bistrian B . Fine vs. coarse complete all-in-one admixture infusions over 96 hours in rats: fat globule size and hepatic function. Clin Nutr. 2008; 27(6):889-94. DOI: 10.1016/j.clnu.2008.08.011. View

13.

van Zanten A, Polderman K, van Geijlswijk I, van der Meer G, Schouten M, Girbes A . Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008; 23(3):422-30. DOI: 10.1016/j.jcrc.2007.11.011. View

14.

Volgyi G, Ruiz R, Box K, Comer J, Bosch E, Takacs-Novak K . Potentiometric and spectrophotometric pKa determination of water-insoluble compounds: validation study in a new cosolvent system. Anal Chim Acta. 2007; 583(2):418-28. DOI: 10.1016/j.aca.2006.10.015. View

15.

Bradley J, Wassel R, Lee L, Nambiar S . Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009; 123(4):e609-13. DOI: 10.1542/peds.2008-3080. View

16.

Allen Jr L, Levinson R, Phisutsinthop D . Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34(9):939-43. View

17.

Trissel L, Gilbert D, Martinez J, Baker M, Walter W, Mirtallo J . Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health Syst Pharm. 1997; 54(11):1295-300. DOI: 10.1093/ajhp/54.11.1295. View

18.

Staven V, Iqbal H, Wang S, Gronlie I, Tho I . Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol. 2016; 69(4):448-462. DOI: 10.1111/jphp.12647. View

19.

Taxis K, Barber N . Incidence and severity of intravenous drug errors in a German hospital. Eur J Clin Pharmacol. 2003; 59(11):815-7. DOI: 10.1007/s00228-003-0689-9. View

20.

Vincent J, Rello J, Marshall J, Silva E, Anzueto A, Martin C . International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009; 302(21):2323-9. DOI: 10.1001/jama.2009.1754. View